According to a report obtained by the Guardian, the cost of importing drugs for a clinical study in Paris and Birmingham has nearly quadrupled to £175,000, significantly impacting NHS cancer patients who are being denied access to life-saving treatments due to Brexit-related expenses. The report highlights how red tape and increased costs following the UK’s departure from the EU are disrupting British clinical trials of innovative cancer therapies. As a result, patients find themselves in a precarious situation, unable to access crucial treatments.
